-

Bausch + Lomb to Participate in Citi Global Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 9:00 a.m. ET.

A live webcast, as well as a post-event recording, will be available on the Investor Relations page of the Bausch + Lomb website: http://ir.bausch.com/investors/events-presentations.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

© 2025 Bausch + Lomb.

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media Contact:
Chris Clark
chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

More News From Bausch + Lomb Corporation

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi...

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has dec...

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to serve all eye care providers, r...
Back to Newsroom